Academic Journal
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
| العنوان: | The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project |
|---|---|
| المؤلفون: | Bellei, Mónica, Foss, Francine M., Shustov, Andrei, Horwitz, Steven M., Marcheselli, Luigi, Kim, Won Seog, Cabrera, María Elena, Dlouhy, Iván, Nagler, Arnon, Advani, Ranjana H., Pesce, Emanuela Anna, Ko, Young-Hyeh, Martínez, Virginia, Montoto, Silvia, Chiattone, Carlos, Moskowitz, Alison, Spina, Michele, Biasoli, Irene, Manni, Martina, Federico, Massimo |
| المصدر: | Haematologica |
| بيانات النشر: | Ferrata Storti Foundation |
| سنة النشر: | 2018 |
| المجموعة: | Universidad de Chile: Repositorio académico |
| مصطلحات موضوعية: | non-hodgkins-lymphomas, response criteria, classification, survival |
| الوصف: | This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation. ; Fondazione Cassa di Risparmio di Modena, Modena, Italy; Associazione Angela Serra per la Ricerca sul Cancro, Modena, Italy; Fondazione Italiana Linfomi (FIL), Alessandria, Italy; Allos Therapeutics, Inc., Westminster, CO, USA; AIRC (Associazione Italiana per la Ricerca sul Cancro) 5x1000: 10007; NIH/NCI ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0390-6078 |
| Relation: | Haematologica, 103(7), 03 julio 2018, 1191-1197 pp.; http://repositorio.uchile.cl/handle/2250/159232 |
| DOI: | 10.3324/haematol.2017.186577 |
| الاتاحة: | https://doi.org/10.3324/haematol.2017.186577 http://repositorio.uchile.cl/handle/2250/159232 |
| Rights: | Attribution-NonCommercial-NoDerivs 3.0 Chile ; http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ |
| رقم الانضمام: | edsbas.4BC6D79B |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 03906078 |
|---|---|
| DOI: | 10.3324/haematol.2017.186577 |